Consequently, Gal-3 is considered a biomarker that is predictive of cardiac remodeling and adverse cardiac events, including the risk of the onset of CHF and myocardial fibrosis [5,9,10,11,12]. The gene discussed is LGALS3; the disease is Myocardial fibrosis.